Compare LBRDA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDA | PTGX |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.4B |
| IPO Year | N/A | 2016 |
| Metric | LBRDA | PTGX |
|---|---|---|
| Price | $34.99 | $119.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $108.23 |
| AVG Volume (30 Days) | 189.0K | ★ 749.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | $109.28 | N/A |
| P/E Ratio | ★ $8.39 | $2,437.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.18 | $49.86 |
| 52 Week High | $100.71 | $126.25 |
| Indicator | LBRDA | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 65.24 |
| Support Level | $31.91 | $94.48 |
| Resistance Level | $34.90 | N/A |
| Average True Range (ATR) | 1.59 | 4.97 |
| MACD | 0.54 | 1.29 |
| Stochastic Oscillator | 55.73 | 74.01 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.